Bruce Boman
Physician in Gladwyne, PA
License number
Pennsylvania DR-0006247
Issued Date
Mar 10, 2008
Expiration Date
Jun 30, 2017
Category
Controlled Substances
Type
Physician CSR
Address
Address
2
Gladwyne, PA 19035
Professional information
Immunoassays To Detect Diseases Or Disease Susceptibility Traits
US Patent:
7981692, Jul 19, 2011
Filed:
Dec 21, 2010
Appl. No.:
12/975270
Inventors:
Bruce M. Boman - Gladwyne PA, US
Assignee:
CA*TX Inc. - Gladwyne PA
International Classification:
G01N 33/53, G01N 33/48, G01N 33/566, G01N 33/567
US Classification:
436501, 436503, 436 63, 436 64, 436504, 436505, 436518, 435 71, 435 792
Abstract:
Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples.
Immunoassays To Detect Diseases Or Disease Susceptibility Traits
US Patent:
7148016, Dec 12, 2006
Filed:
Jan 11, 2000
Appl. No.:
09/480389
Inventors:
Bruce M. Boman - Gladwyne PA, US
International Classification:
G01N 33/53, G01N 33/48, G01N 33/566, G01N 33/567
US Classification:
435 71, 436 63, 436 64, 436501, 436503, 436504, 436505, 436518
Abstract:
Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples.
Immunoassays To Detect Diseases Or Disease Susceptibility Traits
US Patent:
7867717, Jan 11, 2011
Filed:
Oct 10, 2006
Appl. No.:
11/545660
Inventors:
Bruce M. Boman - Gladwyne PA, US
International Classification:
G01N 33/53, G01N 33/48, G01N 33/566, G01N 33/567
US Classification:
435 71, 435 792, 436 63, 436 64, 436501, 436503, 436504, 436505, 436518
Abstract:
Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples.
Dna Sequences Isolated From Human Colonic Epithelial Cells
US Patent:
2003021, Nov 27, 2003
Filed:
Mar 29, 2002
Appl. No.:
10/089887
Inventors:
Bruce Boman - Gladwyne PA, US
Assignee:
CA*TX Inc.
International Classification:
C12Q001/68, G01N033/53, A01K067/027, C07H021/04, C12P021/02, C12N005/06, C07K014/705
US Classification:
435/006000, 435/007100, 435/069100, 435/320100, 435/325000, 530/350000, 536/023500, 800/014000
Abstract:
The present invention discloses novel nucleic acid sequences which are implicated in the growth regulation of the epithelial cells of the colon, and which sequences are differentially expressed in cancerous colon tissues compared to normal colon tissues. These sequences are useful in diagnosing abnormal cell growth, treatment of abnormal cell growth and screening assays for treatments of abnormal cell growth.
Dna Sequences Isolated From Human Colonic Epithelial Cells
US Patent:
2007023, Oct 4, 2007
Filed:
Nov 21, 2006
Appl. No.:
11/603483
Inventors:
Bruce Boman - Gladwyne PA, US
International Classification:
C12Q 1/68, A01K 67/027, A61K 38/00, C07H 21/04, C07K 14/00, G01N 33/53, C07K 16/18, C12N 15/00, C12N 5/06
US Classification:
435006000, 435320100, 435325000, 435007100, 514002000, 530350000, 530387100, 536023500, 536024310, 800013000
Abstract:
The present invention discloses novel nucleic acid sequences which are implicated in the growth regulation of the epithelial cells of the colon, and which sequences are differentially expressed in cancerous colon tissues compared to normal colon tissues. These sequences are useful in diagnosing abnormal cell growth, treatment of abnormal cell growth and screening assays for, treatments of abnormal cell growth.
Stem Cell-Based Methods For Preventing And Treating Tumor
US Patent:
2002006, May 23, 2002
Filed:
Oct 2, 2001
Appl. No.:
09/969892
Inventors:
Bruce Boman - Gladwyne PA, US
International Classification:
A61K038/19, A61K038/18, A61K038/17
US Classification:
424/085100, 514/002000
Abstract:
Stem cell-based methods and compositions for treating and preventing tumorigenesis are disclosed.